JAVELIN PHARMACEUTICALS, Inc. (AM:JAV)
1.47
+0.07 (5.00%)
| JAVELIN PHARMACEUTICALS, Inc. (AM:JAV) Delayed : |
| Previous Close |
$1.40 |
|
52 Week High |
$2.28 |
|
| Open |
$1.42 |
|
52 Week Low |
$0.40 |
| Day High |
$1.55 |
|
P/E |
N/A |
| Day Low |
$1.41 |
|
EPS |
$-0.71 |
| Volume |
319,224 |
|
|
|
| More JAV Info:
Chart
SEC Filings
Profile
Historical
Options
|
-
Nov 10, 2009 07:18 AM
Javelin Pharma (JAV) Posts Q3 Loss of 11c, Misses Views
-
Nov 9, 2009 02:36 PM
Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
-
Aug 11, 2009 12:22 PM
Unusual 11 Mid-Day Movers 8/11: AVNR, RWC, ALC, BEXP Higher; AHR, JAV, SSP, CIT Lower
-
Aug 11, 2009 09:50 AM
Morning Movers 8/11: AVNR, RWC, HLCS, ANPI, ANDS, AGM Higher; JAV, BIDZ, PETD, AHR, CIT, FTK, CLNE Lower
-
Aug 11, 2009 08:47 AM
Javelin Pharmaceuticals (JAV) Reports Ereska (Intranasal Ketamine) Phase III Trial Results in Postoperative Orthopedic Pain
View All Reports
StreetInsider Reports on JAV by Category
Comments on recent JAV articles
Comments on JAV
No comments are currently available.
on Apr 24, 2009
at 12:27 AM Work reduction? This is a very unorthodox approach to developing products that have not yet been approved in the US. Wouldn't you want to simply redirect your focus/resources to speed up clinical and promote development of Ereska and morphine product? I've researched Marty's background and the paper work looks impressive but it's looks like he's simply a figurehead; instead of the people who actually did the work credit, they are promoted out the door and given a pink slip. Typical Driscoll
Article: Javelin Pharmaceuticals (JAV) Cuts Workforce by 15%